• Jobs
  • Startups
  • Hire
LoginSign up

MBX Biosciences

MBX Biosciences has 11 open roles, 5 posted in the last 30 days. Funding stage: Series C. Last round: $34.6M, Aug 5, 2024.

Open roles

  • MBX Biosciences logo
    Director, IT Infrastructure and Security

    MBX Biosciences

    • Burlington, MA
    • Hybrid · Director / Executive
    AI-native
    mbxbio.com
    Posted 1d ago
  • MBX Biosciences logo
    Clinical Scientist (Late Stage)

    MBX Biosciences

    • Burlington, MA
    • Hybrid · Mid-level
    mbxbio.com
    Posted 11d ago
  • MBX Biosciences logo
    Payroll Specialist

    MBX Biosciences

    • Carmel, IN
    • Mid-level
    mbxbio.com
    Posted 22d ago
  • MBX Biosciences logo
    Director, Clinical Operations (Obesity)

    MBX Biosciences

    • Burlington, MA
    • Hybrid · Director / Executive
    mbxbio.com
    Posted 23d ago
  • MBX Biosciences logo
    Associate Director, QA Oversight for QC

    MBX Biosciences

    • Burlington, MA
    • Hybrid · Director / Executive
    mbxbio.com
    Posted 28d ago
  • MBX Biosciences logo
    Scientist, Peptide Chemistry

    MBX Biosciences

    • Boston, MA
    • Junior
    mbxbio.com
    Posted 31d ago
Show all roles

About

MBX Biosciences logo

MBX Biosciences

MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.

Series C
Founded2019
HQCarmel, United States
Size51–200 employees
Unlock human wisdom
ThesisTermsPrivacy
IndustryBiotechnology Research
Funding
  • Series C · $34.6M · Aug 5, 2024
Investors
Frazier Healthcare PartnersNew Enterprise AssociatesTwilight Venture PartnersOrbiMedBioCrossroads
Tech stackmicrosoft-project, microsoft-sharepoint, medidata, smartsheet, microsoft-active-directory, quality-unit, workspace, microsoft-powerpoint, veeva, microsoft-teams

Claim mbxbio.com

Work at mbxbio.com? Sign in to claim this org and manage its profile.

© 2026 Saywise Inc.